Analytical Data
-
基因名
LILRB1
- Application
-
别名
LILRB1；HLA-6.0；HLAG；HLA class I histocompatibility antigen. alpha chain G
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8NHL6
-
表达区间
24-458aa
-
氨基酸序列
GHLPKPTLWAEPGSVITQGSPVTLRCQGGQETQEYRLYREKKTAPWITRI PQELVKKGQFPIPSITWEHAGRYRCYYGSDTAGRSESSDPLELVVTGAYI KPTLSAQPSPVVNSGGNVTLQCDSQVAFDGFILCKEGEDEHPQCLNSQPH ARGSSRAIFSVGPVSPSRRWWYRCYAYDSNSPYEWSLPSDLLELLVLGVS KKPSLSVQPGPIVAPEETLTLQCGSDAGYNRFVLYKDGERDFLQLAGAQP QAGLSQANFTLGPVSRSYGGQYRCYGAHNLSSEWSAPSDPLDILIAGQFY DRVSLSVQPGPTVASGENVTLLCQSQGWMQTFLLTKEGAADDPWRLRSTY QSQKYQAEFPMGPVTSAHAGTYRCYGSQSSKPYLLTHPSDPLELVVSGPS GGPSSPTTGPTSTSGPEDQPLTPTGSDPQSGLGRH
-
分子量
48 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LILRB1, or Leukocyte Immunoglobulin-Like Receptor B1, is a crucial receptor expressed on various immune cells, including monocytes, dendritic cells, and T cells. It plays a significant role in immune regulation by modulating the activation and inhibition of immune responses. The research on LILRB1 has gained momentum due to its involvement in various pathological conditions, including cancer, autoimmune diseases, and infections. The receptor is known to bind to MHC class I molecules, which allows it to participate in the immune evasion mechanisms employed by tumors. The study of LILRB1 recombinant protein is vital for understanding its structural features and interactions with ligands, providing insights into its physiological functions and mechanisms of action. Additionally, the characterization of LILRB1 as a therapeutic target has opened new avenues for the development of treatments that can manipulate immune responses to enhance anti-tumor immunity or restore immune balance in autoimmunity. Vaccines and monoclonal antibodies targeting LILRB1 may also be explored as potential strategies to improve the efficacy of existing therapies. Consequently, the recombinant production of LILRB1 facilitates high-throughput screening and functional assays, making it an essential tool in both basic research and clinical applications concerning immune modulation.
